Pharmacokinetics and Metabolism of [14C] BMS-275183 in Patients With Advanced Cancer
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the Pharmacokinetics, metabolism, and routes and extent of elimination of a single dose of [14C] BMS-275183 over a 10 day period.
United States: Food and Drug Administration
|Local Institution||Austin, Texas|